A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Rezolute
Exelixis
Institute for Clinical and Experimental Medicine
Instituto do Cancer do Estado de São Paulo
National Institutes of Health Clinical Center (CC)
Fundación de investigación HM
RayzeBio, Inc.
National Health Research Institutes, Taiwan
National Institutes of Health Clinical Center (CC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Turning Point Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
RayzeBio, Inc.
Boston Scientific Corporation
National Institutes of Health Clinical Center (CC)
University of Wisconsin, Madison
Centre Oscar Lambret
Stanford University
University of California, San Francisco
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
Grupo Espanol de Tumores Neuroendocrinos
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Tata Memorial Hospital
University of Utah
University of Alberta
Institut du Cancer de Montpellier - Val d'Aurelle
Institut du Cancer de Montpellier - Val d'Aurelle
Chimeric Therapeutics
SAPU NANO (US) LLC
Barbara Ann Karmanos Cancer Institute
Guerbet
Mayo Clinic
Shanghai Zhongshan Hospital
ITM Solucin GmbH
University of Miami
Washington University School of Medicine
Tanabe Pharma America, Inc.
Abramson Cancer Center at Penn Medicine
Nantes University Hospital
Fox Chase Cancer Center
Imperial College London
Perspective Therapeutics
Novelty Nobility, Inc.
University of Michigan Rogel Cancer Center
Tata Memorial Hospital
Sichuan Baili Pharmaceutical Co., Ltd.
Circle Pharma